Hansoh Pharmaceutical (03692.HK) Rises Nearly 3% on New Indication Filing for Anti-CD19 Monoclonal Antibody Inebilizumab

According to the Zhicheng Finance APP, Hansoh Pharma (03692) rose nearly 3% during the trading session. As of the time of writing, it had increased by 2.35%, trading at HK$18.3, with a turnover of HK$60.4331 million.

On the news front, on March 4, according to the official website of the Center for Drug Evaluation (CDE) of the China National Medical Products Administration, a new indication marketing application for Inebilizumab Injection submitted by Horizon Therapeutics, AstraZeneca (AZN.US), and Hansoh Pharma (03692) has been accepted. Inebilizumab is an anti-CD19 monoclonal antibody, which was officially included in the priority review by the CDE in February this year for the treatment of adult patients with Immunoglobulin G4-Related Disease (IgG4-RD). Therefore, it can be speculated that this might be the indication for which the product is being marketed this time.

It is reported that Inebilizumab is a CD19 B-cell depleting antibody. In 2019, Hansoh Pharma entered into a licensing agreement with Viela Bio to obtain the exclusive rights for the development and commercialization of this product in mainland China, Hong Kong, and Macao (Viela Bio was acquired by Horizon Therapeutics in 2021, which was subsequently acquired by Amgen in 2023). Inebilizumab has already been approved for marketing in the United States and China, for the treatment of adult patients with neuromyelitis optica spectrum disorder (NMOSD) who are positive for anti-aquaporin-4 (AQP4) antibodies.